Nature Reviews Cancer

Nature Reviews Cancer (commonly abbreviated as Nat. Rev. Cancer) is an oncology review journal published by Springer Nature. Launched in October 2001 and issued monthly, it aims to be the premier source of reviews and commentaries for the scientific communities it serves, with a 2025 impact factor of 60.7.Nature Reviews Cancer（常用缩写 Nat. Rev. Cancer）是 Springer Nature 旗下肿瘤学领域的综述类期刊，2001 年 10 月创刊并按月刊出版，定位为癌症研究界综述与评论的首要来源，2025 年影响因子为 60.7。^[1]

Scope

Disciplinary focus: the journal strives to publish articles that are authoritative and accessible, enhanced with clearly understandable figures, tables and other display items, and works hard to maximize the usefulness and impact of each article for authors, referees and readers alike.学科定位：期刊以权威、易读并配有清晰易懂的图表与展示材料为目标，为作者、审稿人与读者提供尽可能完善的服务，力求让每一篇文章都发挥最大的效用与影响力；
Subjects covered: the scope spans genomic instability, growth-promoting and growth-inhibitory signals, cancer stem cells, cell death, metabolism, the tumour microenvironment, tumour evolution and heterogeneity, metastasis, carcinogenesis and cancer prevention, cancer diagnosis and prognosis, new approaches to cancer therapy, experimental systems and techniques, cancer-associated disease, and the ethical, legal and social issues surrounding cancer research.选题范围：覆盖基因组不稳定性、促生长信号与抑生长信号的失调、癌症干细胞、细胞死亡、肿瘤细胞的代谢、肿瘤微环境、肿瘤演变与异质性、转移、致癌与癌症预防、癌症诊断与预后、癌症治疗的新途径、实验体系与技术、癌症相关疾病，以及围绕癌症研究的伦理、法律与社会议题；
Content types: the journal publishes Research Highlights, Comment, Review and Perspective articles, with the editorial team selecting and appraising important primary research from elsewhere in the field, and Journal Club features in which specialists discuss individual papers.体裁：刊发研究亮点、评论、综述与观点等体裁，编辑团队会挑选同类期刊中的重要一级研究加以评述，并以期刊俱乐部的形式组织专家对单篇论文展开讨论；
Commissioned model: Reviews and Perspectives are written by leaders in the field at the journal's invitation and subject to rigorous peer review, so complete unsolicited manuscripts are not accepted. Authors may submit proposals for Review-type and Comment-type articles through the online submission system, and these are considered, but the great majority of published content is commissioned.约稿定位：综述与观点均由编辑部约请领域内的领军学者撰写并经严格同行评审，因此期刊不接受直接投来的完整稿件；作者可在在线投稿系统中提交综述类与评论类的选题提案，编辑部会考虑此类提案，但刊载内容以约稿为绝对主体；
Open access: articles can only be published using the subscription route, and the publisher offers no immediate gold open access option and charges no publication fee. Six months after online publication, authors may self-archive the accepted manuscript on their personal website or in a funder or institutional repository.开放获取：文章只能按订阅方式出版，出版方不提供立即开放获取选项，也不收取版面费；作者可在文章在线发表六个月后，将已接受的稿件存入个人主页或资助方与所属机构的知识库；

History

October 2001: the journal was launched as one of the early Nature Reviews titles established by Nature Publishing Group, and together with the other life-science titles in the series it set the template for the monthly review format.2001年10月：期刊创刊，是自然出版集团早期建立的 Nature Reviews 系列刊物之一，与同系列的其他生命科学刊物一起确立了该系列以月度综述为基本体裁的办刊传统。
April 2009: the publisher rebranded eight clinical journals under the Nature Reviews name, taking the series from seven titles to fifteen. This journal kept its own title but thereby came to sit alongside its clinical sister journals under a single brand.2009年4月：出版方把八本临床类刊物统一改冠 Nature Reviews 品牌，Nature Reviews 系列由七本扩至十五本，本刊虽未改名，但由此与临床肿瘤学等姊妹刊并列于同一品牌之下；
New formats: as topics in the field evolved, the journal added compact formats such as Journal Club, Tools of the Trade and Correspondence to appraise individual papers, research platforms and developments across the community.体裁扩充：随着学科热点演变，期刊陆续增设期刊俱乐部、工具评论与通讯等短小体裁，用于快速评述单篇论文、方法平台与学界动态；
The 2020s: the impact factor reached 78.5 in 2022 before easing back to 60.7 in 2025 as the field fluctuated overall, and the journal remains among the most highly ranked oncology titles by impact factor.2020年代：期刊影响因子在 2022 年一度达到 78.5，其后随领域整体波动回落至 2025 年的 60.7，仍稳居肿瘤学影响因子排序前列。
Publisher: Nature Publishing Group was first a publishing division of Macmillan, and in 2015 it merged with the Springer Science and Business Media Group. The title is now published under the Springer Nature name.出版方：自然出版集团先为麦克米伦旗下的出版部门，后于 2015 年与施普林格科学与商业出版集团合并，今日以 Springer Nature 名义出版。^[2]

Editors

Chief Editor: the journal is led by Anna Dart PhD, who joined as an Associate Editor in May 2016, was promoted to Senior Editor in December 2018 and became Chief Editor in May 2022. She is based in the London office and is especially interested in metastasis, the tumour microenvironment, and cancer genetics and epigenetics.主编：现任主编为 Anna Dart 博士，她于 2016 年 5 月以副编辑身份加入本刊，2018 年 12 月升任高级编辑，2022 年 5 月出任主编，常驻伦敦办公室，其研究兴趣集中于转移、肿瘤微环境以及癌症遗传学与表观遗传学。
Senior Editors: Gabrielle Brewer PhD and Daniela Senft PhD serve as Senior Editors, both based in the Berlin office. The former trained in the mechanical role of cancer-associated fibroblasts, and the latter has worked on BCL-2 dysregulation in melanoma and on leukaemia models.高级编辑： Gabrielle Brewer 博士与 Daniela Senft 博士担任高级编辑，两人分别常驻柏林办公室，前者的研究背景为肿瘤相关成纤维细胞，后者曾研究黑色素瘤中BCL-2 蛋白的失调与白血病模型；
No external editorial board: the journal has no external editorial board, and all editorial decisions are made by a team of full-time professional editors with PhD-level scientific training, an arrangement shared across the Nature Reviews portfolio.无外部编委：期刊不设外部编委，所有编辑决定均由一支具有博士学位的全职专业编辑团队集体作出，这套架构同样适用于 Nature Reviews 系列的其他刊物；
Cross-journal team: a Reviews Cross-Journal Editorial Team also works across the Nature Reviews portfolio as needs arise, handling content in the life, clinical, physical and social sciences.跨刊团队：另设跨刊综述编辑团队，按需要在生命、临床、物理与社会科学各领域之间调配人手，以承接不同学科的选题。
Submissions and contact: manuscripts and proposals are submitted through the Nature Publishing Group online submission and tracking system, and general editorial inquiries are addressed to the editorial team, which responds directly.投稿与联系：稿件与选题提案通过自然出版集团的在线投稿与追踪系统提交，一般编辑问询由编辑部统一受理并统一答复。^[3]

References